Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Mersana Therapeutics, Inc. | mer-20170630ex312d2937e.htm |
| EX-31.1 - EX-31.1 - Mersana Therapeutics, Inc. | mer-20170630ex311c14ab1.htm |
| EX-10.1 - EX-10.1 - Mersana Therapeutics, Inc. | mer-20170630ex101c250d6.htm |
| 10-Q - 10-Q - Mersana Therapeutics, Inc. | mer-20170630x10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Mersana Therapeutics, Inc. (the “Company”) for the quarter ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Section 1350 of Chapter 63 of Title 18, United States Code, that to the best of her knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated: August 11, 2017 |
/s/ Anna Protopapas |
|
|
Anna Protopapas |
||
|
President and Chief Executive Officer |
|
Dated: August 11, 2017 |
/s/ Eva Jack |
|
|
Eva Jack |
||
|
Chief Business Officer (Principal Financial Officer) |